Mercedes López Santalla

Mercedes Lopez-Santalla studied Biochemistry at Complutense University of Madrid (1995-2000). In 2001, she started PhD studies in the Program "Medical Immunology: Pathology and Therapeutics" in the Department of Immunology of the Faculty of Medicine at Complutense University, under the supervision of Professor Martin-Villa. Her thesis was focused on the alterations of T lymphocytes from peripheral blood and gastric mucosa of patients with gastric adenocarcinoma and was presented in 2006. During this stage, she completed these studies with a stay at "Walter Reed Army Institute of Research" in Maryland (USA) under the direction of Dr Tsokos for studying the T-cell receptor pathway (2005).

Subsequently, she joined the Department of Immunology and Oncology of the National Centre for Biotechnology which belongs to the Spanish National Research Council in 2006, as a postdoctoral researcher in the Sara Borrell program of the Ministry of Health.She continued with the study of the mechanisms of activation of T lymphocytes from mice and patients with different autoimmune diseases (2006-2012). She completed these studies in the Rheumatology Service/Department of Immunology at La Princesa University Hospital in Madrid (2011-2012).

In 2012, she started working in the Advanced Therapy Unit and Hematopoietic Innovative Therapies Division of CIEMAT/IIS-FJD/CIBERER under the direction of Dr Bueren focusing on immune responses involved in cell therapy with mesenchymal stem cells in autoimmunity.

She has been tutor and participated in the teaching of different degrees and master's degrees at the Complutense, San Pablo CEU, Francisco de Vitoria and La Rioja universities being certificated for associated professor, assistant professor and private university professor by the National Quality and Accreditation Agency (ANECA). Additionally, she is implicated in outreach activities in high schools (secondary schools) and professional training centres organized by the CIEMAT and is reviewer of several scientific journals.

ORCID: 0000-0002-8543-8743

Web of science Researcher ID: L-1335-2015/AAM-6451-2021/AAC-4161-2021

Scopus ID: 6506210282

Publications:

1. Lopez-Santalla M, Garin MI. Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases. Biomedicines. 2021; 9(11):1507. IF: 6.081 (Q1).

2. Lopez-Santalla M, Bueren JA, Garin MI.Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies. EBioMedicine. 2021;69:103427. IF: 11.205 (Q1).

3. Fernandez-Perez R, Lopez-Santalla M, Sánchez-Domínguez R, Alberquilla O, Gutiérrez-Cañas I, Juarranz Y, Bueren JA, Garin MI. Enhanced Susceptibility of Galectin-1 Deficient Mice to Experimental Colitis. Front Immunol. 2021;12:687443. IF: 8.786 (Q1).

4. Lopez-Santalla M, Fernandez-Perez R, Garin MI.Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications. Cells. 2020;9(8):1852. IF: 6.600 (Q2).

5. Lopez-Santalla M, Hervas-Salcedo R, Fernandez-Garcia M, Bueren JA, Garin MI. Cell Therapy With Mesenchymal Stem Cells Induces an Innate Immune Memory Response That Attenuates Experimental Colitis in the Long Term. J Crohns Colitis. 2020;14(10):1424-1435. IF: 9.071 (Q1).

6. Yuste-Calvo C, lopez-Santalla M, Garin MI, Ponz F. Journal of Immunobiology Open Access Theranostic Viral Nanoparticles for Autoimmune Diseases J Immunol Biol. 2020; 5:1.

7. M Martín-Salgado, E Andrada, R Liébana, M Mercedes López-Santalla. Diacylglycerol kinase ζ deficiency triggers early signs of aplastic anemia in mice. BioRXiV 2020.

8. Yuste-Calvo C, Lopez-Santalla M, Zurita L, Cruz-Fernández CF, Sánchez F, Garín MI, Ponz F. Elongated Flexuous Plant Virus-Derived Nanoparticles Functionalized for Autoantibody Detection. Nanomaterials (Basel). 2019;9(10):1438. IF: 4.324 (Q1).

9. Lopez-Santalla M, Mancheño-Corvo P, Escolano A, Menta R, Delarosa O, Redondo JM, Bueren JA, Dalemans W, Lombardo E, Garin MI Comparative Analysis between the In Vivo Biodistribution and Therapeutic Efficacy of Adipose-Derived Mesenchymal Stromal Cells Administered Intraperitoneally in Experimental Colitis. Int J Mol Sci. 2018;19(7):1853. IF: 4.183 (Q1).

10. Villares R, Criado G, Juarranz Y, Lopez-Santalla M, García-Cuesta EM, Rodríguez-Frade JM, Leceta J, Lucas P, Pablos JL, Martínez-A C, Garin MI, Gomariz RP, Mellado M.
Inhibitory Role of Growth Hormone in the Induction and Progression Phases of Collagen-Induced Arthritis. Front Immunol. 2018;9:1165. IF: 4.716 (Q1).

11. Lopez-Santalla M, Mancheño-Corvo P, Escolano A, Menta R, DelaRosa O, Abad JL, Büscher D, Redondo JM, Bueren JA, Dalemans W, Lombardo E, Garin MI. Biodistribution and Efficacy of Human Adipose-Derived Mesenchymal Stem Cells Following Intranodal Administration in Experimental Colitis. Front Immunol. 2017;8:638. IF: 5.511 (Q1).

12. Mancheño-Corvo P, Lopez-Santalla M, Menta R, DelaRosa O, Mulero F, Del Rio B, Ramirez C, Büscher D, Bueren JA, Lopez-Belmonte J, Dalemans W, Garin MI, Lombardo E. Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis. Front Immunol. 2017;8:462. IF: 5.511 (Q1).